<DOC>
	<DOCNO>NCT01097096</DOCNO>
	<brief_summary>This study ass safety , tolerability Abeta-specific antibody response repeat intra-muscular injection adjuvanted CAD106 patient mild Alzheimer 's Disease .</brief_summary>
	<brief_title>Safety , Tolerability Abeta-specific Antibody Response Repeated i.m . Injections Adjuvanted CAD106 Mild Alzheimer Patients</brief_title>
	<detailed_description />
	<mesh_term>Alzheimer Disease</mesh_term>
	<mesh_term>Antibodies</mesh_term>
	<mesh_term>Immunoglobulins</mesh_term>
	<criteria>Male and/or female patient 85 year age ( inclusive ) Diagnosis mild Alzheimer 's Disease MiniMental State Examination ( MMSE ) 20 26 ( inclusive ) screening , untreated stable dose cholinesterase inhibitor memantine last 4 week prior clinical assessment Previously participate AD vaccine study receive active treatment History presence active autoimmune disease History presence seizure disorder Presence significant coronary heart disease and/or cerebrovascular disease Presence neurodegenerative disease and/or psychiatric disorder ( exception successfully treat depression ) Advanced , severe , progressive unstable disease might interfere safety , tolerability pharmacodynamic assessment patient Other protocoldefined inclusion/exclusion criterion may apply</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>85 Years</maximum_age>
	<verification_date>March 2016</verification_date>
	<keyword>Active immunization</keyword>
	<keyword>Alzheimer disease</keyword>
	<keyword>Antibody</keyword>
	<keyword>Central Nervous System Diseases</keyword>
	<keyword>Neurodegenerative disease</keyword>
	<keyword>Vaccine</keyword>
</DOC>